Willingness and hesitancy towards the governmental free human papillomavirus vaccination among parents of eligible adolescent girls in Shenzhen, Southern China
BMC Women's Health · 23.04.2024 · 24 (1)
DOI: 10.1186/s12905-024-03083-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMC Women's Health, online erschienen am 23.04.2024. Verfasst von Dadong Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Maternity and Child Healthcare Hospital, No. 2004 Hongli Road, Shenzhen, China. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Parents, Papillomavirus Infections, Patient Acceptance of Health Care. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill & Melinda Gates Foundation.
Abstract (Originalsprache)
Background
Since 2020, China has actively promoted HPV vaccination for eligible adolescent girls through various pilot programmes. This study investigated parental willingness and hesitancy towards the government-sponsored, free human papillomavirus (HPV) vaccination for eligible adolescent girls in Shenzhen, Southern China.
Methods
From June to August 2022, a cross-sectional survey was conducted with parents of girls entering Grade 7, employing an adapted Vaccine Hesitancy Scale to assess vaccine hesitancy and logistic regression to identify factors influencing willingness to accept the free domestic vaccines.
Results
Although only 3.4% of the 2856 respondents had their daughters vaccinated against HPV prior to the survey, 91.7% were willing to utilise the governmental vaccination services. Parents with children in public schools ( χ 2 = 20.08, p < 0.001), those with more secure medical insurance ( χ 2 = 4.97, p = 0.026), and parents who had received an HPV vaccine themselves ( χ 2 = 28.829, p < 0.001) showed more reluctance towards the free vaccines. Vaccine hesitancy was presented in a mere 2.1% but was a significant predictor of vaccine refusal, even after adjusting for multiple factors (adjusted OR = 15.98, 95% CI: 9.06, 28.20). Notably, about four-fifths of parents of unvaccinated daughters harboured concerns about the safety and efficacy of the domestic vaccine.
Conclusions
Although parents show a strong inclination to utilise the government vaccination services, their vaccine hesitancy, driven by safety concerns and a preference for imported vaccines, remains a significant barrier for rolling out vaccination coverage. This study highlights the need for multifaceted intervention strategies that address these issues to enhance HPV vaccine uptake effectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shenzhen Maternity and Child Healthcare Hospital, No. 2004 Hongli Road, Shenzhen, China.
- Shenzhen Key Laboratory of Modern Toxicology, Shenzhen Medical Key Discipline of Health Toxicology, Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
- Shenzhen Maternity and Child Healthcare Hospital, No. 2004 Hongli Road, Shenzhen, China. wangyueyun@126.com.
Förderung
- Bill & Melinda Gates Foundation
Zitieren
APA
Wu, D., Liu, P., Wang, H., Wan, W., & Wang, Y. (2024). Willingness and hesitancy towards the governmental free human papillomavirus vaccination among parents of eligible adolescent girls in Shenzhen, Southern China. BMC Women's Health, 24(1). https://doi.org/10.1186/s12905-024-03083-2
Vancouver
Wu D, Liu P, Wang H, Wan W, Wang Y. Willingness and hesitancy towards the governmental free human papillomavirus vaccination among parents of eligible adolescent girls in Shenzhen, Southern China. BMC Women's Health. 2024;24(1). doi:10.1186/s12905-024-03083-2
BibTeX
@article{Wu2024,
author = {Wu, Dadong and Liu, Peiyi and Wang, He and Wan, Wenwen and Wang, Yueyun},
title = {Willingness and hesitancy towards the governmental free human papillomavirus vaccination among parents of eligible adolescent girls in Shenzhen, Southern China},
journal = {BMC Women's Health},
year = {2024},
volume = {24},
number = {1},
doi = {10.1186/s12905-024-03083-2}
}
EUVIMED